PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Hisham Shiblaq Sells 247 Shares

PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Hisham Shiblaq sold 247 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $14,093.82. Following the sale, the executive vice president now directly owns 63,133 shares of the company’s stock, valued at $3,602,368.98. This represents a 0.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

PROCEPT BioRobotics Stock Up 1.4 %

Shares of NASDAQ:PRCT traded up $0.77 during trading on Wednesday, reaching $57.80. 517,627 shares of the company traded hands, compared to its average volume of 724,050. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 1-year low of $45.56 and a 1-year high of $103.81. The firm has a fifty day simple moving average of $68.87 and a 200 day simple moving average of $78.75. The firm has a market cap of $3.17 billion, a P/E ratio of -29.64 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The firm had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million. Analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on PRCT shares. Wells Fargo & Company restated an “overweight” rating and issued a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Morgan Stanley cut their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, PROCEPT BioRobotics presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.29.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of hedge funds have recently added to or reduced their stakes in PRCT. Raleigh Capital Management Inc. acquired a new stake in PROCEPT BioRobotics in the fourth quarter valued at approximately $32,000. Thematics Asset Management bought a new position in shares of PROCEPT BioRobotics during the 4th quarter valued at $46,000. Signaturefd LLC lifted its stake in shares of PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company’s stock valued at $55,000 after purchasing an additional 145 shares during the last quarter. IFP Advisors Inc bought a new stake in PROCEPT BioRobotics in the fourth quarter worth $58,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in PROCEPT BioRobotics in the third quarter worth $64,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).